joimax® announces strategic partnership with NAMSA | Business


IRVINE, Calif .– (BUSINESS WIRE) – July 21, 2021–

joimax®, the German market leader in technologies and training methods for fully endoscopic and minimally invasive spinal surgery, is pleased to announce a new strategic partnership with NAMSA, the only contract research organization (CRO) in full continuum in the world focused exclusively on medical devices. Recognized as a leader in reimbursement strategies, with years of experience working with public and private payers, NAMSA will assist joimax® clients with reimbursement support services, including prior authorization and support. to calls, across the United States.

“We are delighted that NAMSA is serving as an exclusive partner in helping patients access joimax® endoscopic technologies,” said Maximilian Ries, general manager of joimax®. “We are optimistic that with the help of NAMSA and the nearly 5,000 clinical papers on endoscopic spine surgery, we will continue to expand coverage of this important minimally invasive technology.”

Since the inception of the American Medical Association CPT® 62380 Medical Procedure Code, Endoscopic Decompression of Neural Elements and / or Excision of Herniated Intervertebral Discs, in 2017, the use of endoscopic spinal procedures has increased.

For more details, visit

About joimax®

Founded in Karlsruhe, Germany, in 2001, joimax® is the leading developer and distributor of complete systems for fully endoscopic and minimally invasive spinal surgery. With TESSYS® (transforaminal), iLESSYS® (interlaminar) and CESSYS® (cervical) endoscopic surgical systems for decompression procedures, MultiZYTE® for the treatment of facet and sacroiliac joint pain, EndoLIF® and Percusys® for stabilization Minimally invasive endoscopically assisted, established systems are provided, addressing a range of indications. In procedures for herniated disc, stricture, pain treatment or spinal stabilization treatment, surgeons use joimax® technologies to operate through small incisions under local or complete anesthesia, via tissue and muscle corridors and to through natural openings in the spinal canal, for example, the foramen intervertebral canal, the so-called “Kambin’s triangle”.


Helping medical device sponsors improve healthcare since 1967, NAMSA is the world’s only full-continuum contract research organization (CRO) focused on medical devices. With its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, delivering only the most proven solutions to move customers’ products through the development cycle in a way efficient and profitable. Medical device tests; regulatory, reimbursement and quality advice; and clinical research services; NAMSA is the industry’s premier trusted partner for successful development and commercialization results.

See the source version on

CONTACT: Press contact Germany:

joimax® GmbH

Nicole Read

[email protected]

US Press Contact:

Tony Troncale

joimax® inc.

[email protected]




SOURCE: joimax

Copyright Business Wire 2021.

PUB: 07/21/2021 08:33 / DISC: 07/21/2021 08:33

Copyright Business Wire 2021.

Source link

Leave A Reply

Your email address will not be published.